Verified July 2026 · Cited to primary sources
KPV: Evidence Grade D. Animal studies only, unproven in humans.
An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans.
The honest verdict
KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials.
KPV at a glance
- Class
- Synthetic tripeptide (C-terminal fragment of α-MSH)
- Mechanism
- Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.
- Also known as
- Lysine-Proline-Valine, α-MSH C-terminal tripeptide
- Research applications
- Gut/IBD-type inflammation (cell and animal colitis models)
- Skin inflammation
- Forms
- subcutaneous injection, oral capsule, topical
- Legal status
- Under FDA review
- WADA (anti-doping)
- Not prohibited (no performance mechanism)
- Evidence grade
- Grade DAnimal studies only, unproven in humans
How we grade evidence
Every grade comes from a fixed A to F rubric: human-trial strength, not hype or affiliate status. Last verified July 6, 2026.
What is KPV?
Compound class: Synthetic tripeptide (C-terminal fragment of α-MSH)
Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.
How strong is the evidence for KPV?
Grade D: preclinical only (cell and animal colitis models), no published human RCT (rule 5 fired).
Primary sources (3)
Is KPV legal? (Status July 2026)
Regulatory limbo; the July 2026 PCAC panel has advised, the FDA decision is pending.
July 2026 PCAC vote
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the 503A compounding list (8 to 6, with 1 abstention), overriding the FDA's own scientists. That is an advisory recommendation, not legalization: the FDA still makes the final decision and has not acted, so KPV is not yet legally compoundable. Track the FDA peptide vote →
What is KPV used for?
KPV is marketed for the goals below. See how it ranks against other peptides in each, by evidence, not hype.
What does KPV cost, and how do you access it legally?
Typical cost
UNKNOWN
No verified clinic price anchor in the research; marked UNKNOWN.
No legal supervised access route right now.
KPV has no compliant US route today while its compounding status is under FDA review. Vials sold "for research use only" are a gray-market fig-leaf, not a legal loophole, so we don't link them. If you pursue KPV, do it with a licensed clinician, and re-check its legal status first.
Telehealth programs do advertise several compounds in this position as prescribable online. We checked those advertised menus against the law in peptide telehealth programs.
Is KPVsafe? Side effects & risks
No human safety data; gray-market only. The FDA's own reviewers found no human clinical studies supporting the nominated use. Not listed as WADA-prohibited (no performance mechanism), but that is not a safety endorsement.
Medical disclaimer: This page is independent editorial information, not medical advice, and Best Peptide For That is not a medical provider. We do not provide dosing. Talk to a licensed clinician before starting, stopping, or changing any peptide or medication. Full medical disclaimer.
Free tool
Peptide reconstitution calculator
Enter the mg in the vial and the ml of bacteriostatic water, and get the concentration plus the units to draw on an insulin syringe. It does the arithmetic on your numbers, and it never suggests a dose. See all four calculators.
FAQ
KPV FAQ
What is KPV used for?
KPV is marketed for gut inflammation (IBD-type symptoms) and skin inflammation based on its anti-inflammatory action in cell and animal models. There are no human efficacy trials, so those uses are unproven: Grade D on our scale. The July 2026 PCAC vote was about legal compounding access, not proof that it works.
Is KPV legal now that PCAC voted for it?
Not yet. On July 23, 2026 the PCAC panel voted 8 to 6 (1 abstention) to recommend adding KPV to the 503A compounding list, but that recommendation is advisory. The FDA has not acted on it, so there is still no legal supervised US route and access remains gray-market only.
Is KPV FDA approved, and what human data does the FDA have on it?
KPV is not FDA approved, and no application for approval is pending. Two different questions get collapsed here constantly, so keep them apart. Approval is the FDA agreeing a drug is safe and effective for an indication after reviewing trial data. Compounding eligibility, which is what the July 2026 PCAC vote was about, is the FDA deciding whether a pharmacy may lawfully make the substance at all. KPV has neither. On the human data specifically: the FDA's own reviewers found no human clinical studies supporting the nominated use of wound healing and inflammatory conditions, and we have found no published human randomized trial either, which is why the grade is D rather than C. The panel recommended it anyway, 8 to 6 with 1 abstention, over that staff objection. So a recommendation here rests on preclinical evidence, and it is not a finding that KPV works in people.
From our portfolio
Tracking KPV?
Titrate is an iOS app for logging doses, schedules and progress over time, with a reconstitution calculator built in. It tracks, it does not prescribe.
Compare KPV with…
Head-to-head evidence-grade matchups people weigh against KPV.
Keep reading
BPC-157
The most-hyped, least-human-proven "healing" peptide. Extensive rodent data, zero published human trials.
Grade DTB-500
The other half of the "wolverine stack." Soft-tissue recovery claims, but only animal data for the fragment actually sold.
Grade DEpitalon
A longevity and anti-aging peptide built on small, low-quality Russian studies. The claims far outrun the evidence.
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.